triple agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
A lipopeptide is a molecule consisting of a lipid connected to a peptide. They are able to self-assemble into different structures. Many bacteria produce these molecules as a part of their metabolism, especially those of the genus Bacillus, Pseudomonas and Streptomyces. Certain lipopeptides are used as antibiotics. Due to the structural and molecular properties such as the fatty acid chain, it poses the effect of weakening the cell function or destroying the cell. Other lipopeptides are toll-like receptor agonists. Certain lipopeptides can have strong antifungal and hemolytic activities. It has been demonstrated that their activity is generally linked to interactions with the plasma membrane, and sterol components of the plasma membrane could play a major role in this interaction. It is a general trend that adding a lipid group of a certain length (typically C10–C12) to a lipopeptide will increase its bactericidal activity. Lipopeptides with a higher amount of carbon atoms, for example 14 or 16, in its lipid tail will typically have antibacterial activity as well as anti-fungal activity. Therefore, an increase in the alkyl chain can make lipopeptides soluble in water. As well, it opens the cell membrane of the bacteria, so antimicrobial activity can take place. Lipopeptide detergents (LPDs) are composed of amphiphiles and two alkyl chains which are located on the last part of the peptide backbone. They were designed to mimic the architecture of the native membranes in which two alkyl chains in a lipid molecule facially interact with the hydrophobic segment of MPs.
Thus, the ability of low doses of trazodone to improve sleep in depressed patients may be an important mechanism whereby trazodone can augment the efficacy of other antidepressants. Trazodone's potent α1-adrenergic blockade may cause some side effects like orthostatic hypotension and sedation. Conversely, along with 5-HT2A and H1 receptor antagonism, it may contribute to its efficacy as a hypnotic. Trazodone lacks any affinity for the muscarinic acetylcholine receptors, so does not produce anticholinergic side effects. mCPP, a non-selective serotonin receptor modulator and serotonin releasing agent, is an active metabolite of trazodone and has been suggested to possibly play a role in its therapeutic benefits. However, research has not supported this hypothesis and mCPP might actually antagonize the efficacy of trazodone as well as produce additional side effects.
== Methodology == Using the PDCAAS method, the protein quality rankings are determined by comparing the amino acid profile of the specific food protein against a standard amino acid profile with the highest possible score being a 1.0. This score means, after digestion of the protein, it provides per unit of protein 100% or more of the indispensable amino acids required. The formula for calculating the PDCAAS percentage is: FTPD × AAS × 100%, where FTPD is fecal true digestibility and AAS is the amino acid score.
where I is the identity tensor. The displacement of a body may be expressed in the form x = F(X), where X is the reference position of material points of the body; displacement has units of length and does not distinguish between rigid body motions (translations and rotations) and deformations (changes in shape and size) of the body. The spatial derivative of a uniform translation is zero, thus strains measure how much a given displacement differs locally from a rigid-body motion. A strain is in general a tensor quantity. Physical insight into strains can be gained by observing that a given strain can be decomposed into normal and shear components. The amount of stretch or compression along material line elements or fibers is the normal strain, and the amount of distortion associated with the sliding of plane layers over each other is the shear strain, within a deforming body. This could be applied by elongation, shortening, or volume changes, or angular distortion. The state of strain at a material point of a continuum body is defined as the totality of all the changes in length of material lines or fibers, the normal strain, which pass through that point and also the totality of all the changes in the angle between pairs of lines initially perpendicular to each other, the shear strain, radiating from this point. However, it is sufficient to know the normal and shear components of strain on a set of three mutually perpendicular directions.
The homeostatic mechanism which controls the plasma sodium concentration is rather more complex than most of the other homeostatic mechanisms described on this page. The sensor is situated in the juxtaglomerular apparatus of kidneys, which senses the plasma sodium concentration in a surprisingly indirect manner. Instead of measuring it directly in the blood flowing past the juxtaglomerular cells, these cells respond to the sodium concentration in the renal tubular fluid after it has already undergone a certain amount of modification in the proximal convoluted tubule and loop of Henle. These cells also respond to rate of blood flow through the juxtaglomerular apparatus, which, under normal circumstances, is directly proportional to the arterial blood pressure, making this tissue an ancillary arterial blood pressure sensor. In response to a lowering of the plasma sodium concentration, or to a fall in the arterial blood pressure, the juxtaglomerular cells release renin into the blood. Renin is an enzyme which cleaves a decapeptide (a short protein chain, 10 amino acids long) from a plasma α-2-globulin called angiotensinogen. This decapeptide is known as angiotensin I. It has no known biological activity. However, when the blood circulates through the lungs a pulmonary capillary endothelial enzyme called angiotensin-converting enzyme (ACE) cleaves a further two amino acids from angiotensin I to form an octapeptide known as angiotensin II. Angiotensin II is a hormone which acts on the adrenal cortex, causing the release into the blood of the steroid hormone, aldosterone.
Sources: en.wikipedia.org
The Scottish Government loses a non-binding vote calling for the rollout of free school meals to all primary school pupils, with MSPs voting 64–2 for the motion. 13 September – Former nurse Adele Rennie is sentenced to two years and four months in prison and placed on the sex offenders' register for ten years after pleading guilty to stalking a woman online, while posing as a man, after the dating app Tinder matched them. 15 September – The A83 road in Argyll is reopened with a slight diversion after heavy rain caused a 500 tonne landslide. 17 September – Glasgow is formally selected as the host city of the Commonwealth Games in 2026. 18 September – Scotland experiences its warmest September day since 2019, with temperatures reaching 25 °C. 19 September – The Scottish Government temporarily pauses a ban on wood burning stoves in new properties and property conversions following a review of the legislation. Greenock Morton F.C. dismisses player Jay Emmanuel-Thomas after he appeared in court accused of attempting to orchestrate the smuggling of drugs into the UK. 20 September – A woman juror who used the Right Move app to research the floorplan of a house similar to one that was the scene of a rape during a trial is fined for contempt of court. 24 September – Official figures show the number of households living in temporary accommodation has reached a record high, with 16,300 households in the system as of March 2024, the highest since records began in 2002.
Adipose tissue (also known as body fat or simply fat) is a loose connective tissue composed mostly of adipocytes. It also contains the stromal vascular fraction of cells including preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells such as adipose tissue macrophages. Its main role is to store energy in the form of lipids, although it also cushions and insulates the body. Previously treated as being hormonally inert, in recent years adipose tissue has been recognized as a major endocrine organ, as it produces hormones such as leptin, estrogen, resistin, and cytokines (especially TNFα). In obesity, adipose tissue is implicated in the chronic release of pro-inflammatory markers known as adipokines, which are responsible for the development of metabolic syndrome—a constellation of diseases including type 2 diabetes, cardiovascular disease and atherosclerosis. Adipose tissue is derived from preadipocytes and its formation appears to be controlled in part by the adipose gene. The two types of adipose tissue are white adipose tissue (WAT), which stores energy, and brown adipose tissue (BAT), which generates body heat. Adipose tissue—more specifically brown adipose tissue—was first identified by the Swiss naturalist Conrad Gessner in 1551.
Pain in the involved body part Temporarily decreased organ function Later symptoms are closely related to infarction of the affected tissue. This may cause permanently decreased organ function. For example, symptoms of myocardial infarction mainly include chest pain, dyspnea, diaphoresis (an excessive form of sweating), weakness, light-headedness, nausea, vomiting, and palpitations. Symptoms of limb infarction include coldness, decreased or no pulse beyond the site of blockage, pain, muscle spasm, numbness and tingling, pallor and muscle weakness, possibly to the grade of paralysis in the affected limb.
==== Cybercrime ==== Generative AI's ability to create realistic fake content has been exploited in numerous types of cybercrime, including phishing scams. Deepfake video and audio have been used to create disinformation and fraud. In 2020, former Google click fraud czar Shuman Ghosemajumder argued that once deepfake videos become perfectly realistic, they would stop appearing remarkable to viewers, potentially leading to uncritical acceptance of false information. Additionally, large language models and other forms of text-generation AI have been used to create fake reviews of e-commerce websites to boost ratings. Cybercriminals have created large language models focused on fraud, including WormGPT and FraudGPT. A 2023 study showed that generative AI can be vulnerable to jailbreaks, reverse psychology and prompt injection attacks, enabling attackers to obtain help with harmful requests, such as for crafting social engineering and phishing attacks. Additionally, other researchers have demonstrated that open-source models can be fine-tuned to remove their safety restrictions at low cost.
Sources: en.wikipedia.org
Bolsonaro has been married three times and has five children. His first wife was Rogéria Nantes Braga, with whom he has three sons: Flávio, Carlos, and Eduardo. His second marriage was with Ana Cristina Valle, with whom he has a son, Jair Renan. In 2007, he married his third wife, Michelle de Paula Firmo Reinaldo, with whom he has a daughter named Laura. While working in Congress, Bolsonaro hired Michelle as a secretary and over the next two years she received promotions and her salary more than tripled. He was forced to fire her after the Supreme Federal Court ruled that nepotism is illegal in the public administration. In 2018 Bolsonaro and his wife lived in Barra da Tijuca, Rio de Janeiro. Bolsonaro has three granddaughters, two by Flávio and one by Eduardo. Bolsonaro is Catholic. On 25 October 2018 he was presented with an honorary black belt by Robson Gracie despite never having trained Brazilian jiu-jitsu. On January 9, 2023, Bolsonaro was taken to AdventHealth Celebration with abdominal pain. On September 16, 2025, Bolsonaro's son said he was transported to a hospital in Brasília after reportedly feeling sick. The next day, it was announced that Bolsonaro was diagnosed with an early type of skin cancer.
=== Legal status === Mirdametinib was approved for medical use in the United States in February 2025. In May 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Ezmekly, intended for the treatment of plexiform neurofibromas (PN) in adults and children from two years of age with neurofibromatosis type 1 (NF1). The applicant for this medicinal product is SpringWorks Therapeutics Ireland Limited. Mirdametinib was authorized for medical use in the EU in July 2025.
=== Role in neonatal immunity across species === The function of FcRn in neonatal immunity differs across species. In humans, FcRn in the placenta transfers maternal IgG to the fetus during gestation. In rodents, maternal IgG is delivered postnatally through FcRn-mediated uptake in the neonatal gut. Species like piglets and foals, which lack prenatal IgG transfer due to their placental structure, depend entirely on intestinal FcRn to absorb IgG from colostrum shortly after birth. These species-specific mechanisms reflect evolutionary adaptations in FcRn expression and function across mammals.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.